<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Urol</journal-id><journal-id journal-id-type="iso-abbrev">World J Urol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>World Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">0724-4983</issn><issn pub-type="epub">1433-8726</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12050225</article-id><article-id pub-id-type="pmcid-ver">PMC12050225.1</article-id><article-id pub-id-type="pmcaid">12050225</article-id><article-id pub-id-type="pmcaiid">12050225</article-id><article-id pub-id-type="pmid">40320496</article-id><article-id pub-id-type="doi">10.1007/s00345-025-05545-0</article-id><article-id pub-id-type="publisher-id">5545</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of chemotherapy on cancer specific mortality in female locally advanced urethral cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Le</surname><given-names initials="QC">Quynh Chi</given-names></name><address><email>d.le@med.uni-frankfurt.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pe&#241;aranda</surname><given-names initials="NR">Natali Rodriguez</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marmiroli</surname><given-names initials="A">Andrea</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>di Bello</surname><given-names initials="F">Francesco</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Longoni</surname><given-names initials="M">Mattia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Falkenbach</surname><given-names initials="F">Fabian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Catanzaro</surname><given-names initials="C">Calogero</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nicolazzini</surname><given-names initials="M">Michele</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tian</surname><given-names initials="Z">Zhe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goyal</surname><given-names initials="JA">Jordan A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Siech</surname><given-names initials="C">Carolin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garcia</surname><given-names initials="CC">Cristina Cano</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Saad</surname><given-names initials="F">Fred</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schiavina</surname><given-names initials="R">Riccardo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Micali</surname><given-names initials="S">Salvatore</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Puliatti</surname><given-names initials="S">Stefano</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>De Cobelli</surname><given-names initials="O">Ottavio</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Briganti</surname><given-names initials="A">Alberto</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Graefen</surname><given-names initials="M">Markus</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Palumbo</surname><given-names initials="C">Carlotta</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Volpe</surname><given-names initials="A">Alessandro</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kluth</surname><given-names initials="LA">Luis A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chun</surname><given-names initials="FKH">Felix K-H.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karakiewicz</surname><given-names initials="PI">Pierre I.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0161xgx34</institution-id><institution-id institution-id-type="GRID">grid.14848.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2104 2136</institution-id><institution>Cancer Prognostics and Health Outcomes Unit, Division of Urology, </institution><institution>University of Montr&#233;al Health Center, </institution></institution-wrap>Montr&#233;al, Qu&#233;bec Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04cvxnb49</institution-id><institution-id institution-id-type="GRID">grid.7839.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9721</institution-id><institution>Department of Urology, </institution><institution>Goethe University Frankfurt, University Hospital, </institution></institution-wrap>Frankfurt am Main, Germany </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01111rn36</institution-id><institution-id institution-id-type="GRID">grid.6292.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 1758</institution-id><institution>Department of Urology, </institution><institution>University of Bologna, St. Orsola-Malpighi Hospital, </institution></institution-wrap>Bologna, Italy </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02d4c4y02</institution-id><institution-id institution-id-type="GRID">grid.7548.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2169 7570</institution-id><institution>Department of Urology, AOU di Modena, </institution><institution>University of Modena and Reggio Emilia, </institution></institution-wrap>Modena, Italy </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vr0ne26</institution-id><institution-id institution-id-type="GRID">grid.15667.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 0843</institution-id><institution>Department of Urology, </institution><institution>IEO European Institute of Oncology, IRCCS, </institution></institution-wrap>Via Ripamonti 435, Milan, Italy </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00wjc7c48</institution-id><institution-id institution-id-type="GRID">grid.4708.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 2822</institution-id><institution>Universit&#224; degli Studi di Milano, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01gmqr298</institution-id><institution-id institution-id-type="GRID">grid.15496.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0439 0892</institution-id><institution>Vita-Salute San Raffaele University, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/039zxt351</institution-id><institution-id institution-id-type="GRID">grid.18887.3e</institution-id><institution-id institution-id-type="ISNI">0000000417581884</institution-id><institution>Division of Experimental Oncology, Unit of Urology, </institution><institution>URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, </institution></institution-wrap>Milan, Italy </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01zgy1s35</institution-id><institution-id institution-id-type="GRID">grid.13648.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 3484</institution-id><institution>Martini-Klinik Prostate Cancer Center, </institution><institution>University Hospital Hamburg-Eppendorf, </institution></institution-wrap>Hamburg, Germany </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04387x656</institution-id><institution-id institution-id-type="GRID">grid.16563.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 3741</institution-id><institution>Division of Urology, Department of Translational Medicine, </institution><institution>University of Eastern Piedmont, Maggiore della Carit&#224; Hospital, </institution></institution-wrap>Novara, Italy </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048tbm396</institution-id><institution-id institution-id-type="GRID">grid.7605.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2336 6580</institution-id><institution>Division of Urology, Department of Oncology, </institution><institution>University of Turin, </institution></institution-wrap>Orbassano, Italy </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05290cv24</institution-id><institution-id institution-id-type="GRID">grid.4691.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0790 385X</institution-id><institution>Department of Neurosciences, Science of Reproduction and Odontostomatology, </institution><institution>University of Naples Federico II, </institution></institution-wrap>Naples, Italy </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>43</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">487918</issue-id><elocation-id>266</elocation-id><history><date date-type="received"><day>9</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-06 00:25:21.020"><day>06</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="345_2025_Article_5545.pdf"/><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">To quantify the effect of chemotherapy (CHT) in locally advanced female primary urethral cancer (fPUC).</p></sec><sec><title>Methods</title><p id="Par2">In the Surveillance, Epidemiology and Ends Results (SEER) database (2000&#8211;2021), we identified 295 fPUC patients with locally advanced stage treated with local therapy (surgery or radiation or both) with or without CHT. Multivariable Cox regression models addressed cancer specific mortality free survival (CSM). Sample power analyses were computed.</p></sec><sec><title>Results</title><p id="Par3">Of 295 fPUC patients, 141 (48%) underwent CHT. CHT rates increased from 40 to 61% (&#916;22%) over the study span (2000&#8211;2021). Five-year CSM rates of CHT exposed vs. CHT-na&#239;ve patients were 58 vs. 43% (&#916;15%). In multivariable Cox regression models (age and histology adjusted) CHT independently predicted lower CSM (HR&#8201;=&#8201;0.67, <italic toggle="yes">p</italic>&#8201;=&#8201;0.027). In squamous cell carcinoma (SCC) subgroup, CHT also independently predicted lower CSM (HR&#8201;=&#8201;0.64, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01). In urothelial carcinoma (HR&#8201;=&#8201;0.63, <italic toggle="yes">p</italic>&#8201;=&#8201;0.2) and adenocarcinoma (HR&#8201;=&#8201;0.7, <italic toggle="yes">p</italic>&#8201;=&#8201;0.7) independent predictor status could not be demonstrated. Small sample sizes in urothelial carcinoma subgroup (UC) and adenocarcinoma subgroup (ADK) undermined the power of the analyses to as low as 48% in UC and 46% in ADK, respectively, versus ideal 80% power.</p></sec><sec><title>Conclusion</title><p id="Par4">In fPUC patients, CHT independently predicts lower CSM. This effect is generalizable to SCC patients. The same relationship between CHT status and CSM is also operational in UC and ADK subgroups, but limited power undermined confirmation of its&#8217; statistical significance.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Locally advanced urethral cancer</kwd><kwd>Females</kwd><kwd>Chemotherapy</kwd><kwd>Cancer specific mortality</kwd></kwd-group><funding-group><award-group><funding-source><institution>Johann Wolfgang Goethe-Universit&#228;t, Frankfurt am Main (1022)</institution></funding-source></award-group><open-access><p>Open Access funding enabled and organized by Projekt DEAL.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Primary urethral cancer (PUC) accounts for less than 1% of urological malignancies. Its&#8217; aged-standardized rate is 1.5 per million in females and 4.3 per million in males in North America [<xref ref-type="bibr" rid="CR1">1</xref>]. Due to male predominance of PUC [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], most studies address mainly males, for example Gakis et al. (<italic toggle="yes">n</italic>&#8201;=&#8201;154) reported 70% male membership, Wenzel et al. (<italic toggle="yes">n</italic>&#8201;=&#8201;1073) 65% male membership and Sui et al. (<italic toggle="yes">n</italic>&#8201;=&#8201;2137) 60% male membership [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. In consequence, treatment types and cancer specific mortality (CSM) rates in female PUC (fPUC) are relatively unknown. Unfortunately, only three analyses specifically examined PUC in female patients. For example Derksen et al. (1989&#8211;2008) described 91 fPUC vs. Peyton et al. (2003&#8211;2017) described 39 fPUC vs. Lee et al. (1997&#8211;2017) described 32 fPUC. However, none of these studies specifically examined locally advanced fPUC or the association between CHT and CSM.</p><p id="Par6">Within PUC, locally advanced patients are known to harbor suboptimal cancer control outcomes. However, in these individuals, it is possible to improve cancer control outcomes by virtue of optimizing treatment intensity. To the best of our knowledge, no study on locally advanced fPUC was reported so far.</p><p id="Par7">We addressed this knowledge gap with the intent of quantifying the association between CHT and CSM in this locally advanced fPUC. We hypothesize that locally advanced fPUC benefit of CHT as recommended by guideline [<xref ref-type="bibr" rid="CR1">1</xref>]. Moreover, we postulated that CHT use is associated with lower CSM. To examine these hypotheses, we relied on locally advanced fPUC from within the SEER database (2000&#8211;2021).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source and study population</title><p id="Par8">The SEER database provides cancer statistics for approximately 47.9% of the United States population [<xref ref-type="bibr" rid="CR7">7</xref>]. Within the SEER database (2000&#8211;2021), we identified fPUC with locally advanced stage (T3-T4, N1-N3, M0) aged&#8201;&#8805;&#8201;18 years with histologically confirmed PUC (International Classification of Disease for Oncology [ICD-10] site code 68.0) with follow-up-data. Excluded were all autopsy- or death certificate-only cases, as well as patients with unknown histology, unknown stage, histological subtypes other than urothelial (UC), squamous cell carcinoma (SCC) or adenocarcinoma (ADK) or patients who have not underwent either surgery or radiotherapy or both. Due to the anonymous nature of the SEER database, study-specific Institutional Review Board approval was waived.</p></sec><sec id="Sec4"><title>Statistical analyses</title><p id="Par9">Baseline characteristics of locally advanced fPUC patients were tabulated (Table <xref rid="Tab1" ref-type="table">1</xref>). Kaplan-Meier plots graphically depicted CSM rates (Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). Univariable and multivariable Cox regression models addressed CSM (Tables&#160; <xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>). Variance inflation factors were addressed to avoid co-linearity within the multivariable Cox regression models. No co-linearity was found in the models. Finally, sample-/ power analyses were computed. Statistical tests were two-sided with a level of significance set at <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. R software environment (R Version 4.4.0, The R Foundation for Statistical Computing, Vienna, Austria) was applied for graphics and statistical computing.</p><p id="Par10">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Kaplan-Meier-plots depicting cancer specific mortality-free survival in 295 locally advanced female urethral cancer patients, CHT&#8201;=&#8201;Chemotherapy</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e493" position="float" orientation="portrait" xlink:href="345_2025_5545_Fig1_HTML.jpg"/></fig>
</p><p id="Par11">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Kaplan Meier curves depicting cancer specific mortality free survival in 295 locally advanced female urethral cancer patients according to histological subtypes, <bold>A</bold>) squamous cell carcinoma, <bold>B</bold>) urothelial carcinoma, and <bold>C</bold>) adenocarcinoma, CHT&#8201;=&#8201;Chemotherapy</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e513" position="float" orientation="portrait" xlink:href="345_2025_5545_Fig2_HTML.jpg"/></fig>
</p><p id="Par12">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Descriptive characteristics of 295 female urethral cancer patients with locally advanced stages according to receipt of chemotherapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristic</th><th align="left" colspan="1" rowspan="1">Overall <break/><italic toggle="yes">N</italic>&#8201;=&#8201;295<sup>1</sup></th><th align="left" colspan="1" rowspan="1">Chemotherapy received, <break/><italic toggle="yes">n</italic>&#8201;=&#8201;141 (48%)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">Chemotherapy naive, <break/><italic toggle="yes">n</italic>&#8201;=&#8201;154 (52%)<sup>1</sup></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Age</bold>
</td><td align="left" colspan="1" rowspan="1"><p>66 </p><p>(58, 74)</p></td><td align="left" colspan="1" rowspan="1">65 (59, 74)</td><td align="left" colspan="1" rowspan="1">66 (58, 75)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Follow-Up</bold>
</td><td align="left" colspan="1" rowspan="1"><p>31 </p><p>(13, 87)</p></td><td align="left" colspan="1" rowspan="1">34 (15, 98)</td><td align="left" colspan="1" rowspan="1">26 (12, 69)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Histology</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Urethral</td><td align="left" colspan="1" rowspan="1">86 (29%)</td><td align="left" colspan="1" rowspan="1">50 (35%)</td><td align="left" colspan="1" rowspan="1">36 (23%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Squamous cell</td><td align="left" colspan="1" rowspan="1">70 (24%)</td><td align="left" colspan="1" rowspan="1">35 (25%)</td><td align="left" colspan="1" rowspan="1">35 (23%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Adenocarcinoma</td><td align="left" colspan="1" rowspan="1">139 (47%)</td><td align="left" colspan="1" rowspan="1">56 (40%)</td><td align="left" colspan="1" rowspan="1">83 (54%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>T-Stage</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">T1</td><td align="left" colspan="1" rowspan="1">17 (5.8%)</td><td align="left" colspan="1" rowspan="1">15 (10%)</td><td align="left" colspan="1" rowspan="1">3 (1.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">T2</td><td align="left" colspan="1" rowspan="1">55 (19%)</td><td align="left" colspan="1" rowspan="1">25 (18%)</td><td align="left" colspan="1" rowspan="1">30 (19%)</td></tr><tr><td align="left" colspan="1" rowspan="1">T3</td><td align="left" colspan="1" rowspan="1">198 (67%)</td><td align="left" colspan="1" rowspan="1">88 (62%)</td><td align="left" colspan="1" rowspan="1">110 (71%)</td></tr><tr><td align="left" colspan="1" rowspan="1">T4</td><td align="left" colspan="1" rowspan="1">20 (7%)</td><td align="left" colspan="1" rowspan="1">10 (7%)</td><td align="left" colspan="1" rowspan="1">10 (7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">TX</td><td align="left" colspan="1" rowspan="1">4 (2%)</td><td align="left" colspan="1" rowspan="1">3 (2%)</td><td align="left" colspan="1" rowspan="1">1 (1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>N-Stage</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">N0</td><td align="left" colspan="1" rowspan="1">176 (60%)</td><td align="left" colspan="1" rowspan="1">61 (43%)</td><td align="left" colspan="1" rowspan="1">115 (75%)</td></tr><tr><td align="left" colspan="1" rowspan="1">N1</td><td align="left" colspan="1" rowspan="1">44 (15%)</td><td align="left" colspan="1" rowspan="1">30 (21%)</td><td align="left" colspan="1" rowspan="1">14 (9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">N2</td><td align="left" colspan="1" rowspan="1">63 (21%)</td><td align="left" colspan="1" rowspan="1">45 (32%)</td><td align="left" colspan="1" rowspan="1">18 (12%)</td></tr><tr><td align="left" colspan="1" rowspan="1">NX</td><td align="left" colspan="1" rowspan="1">12 (4%)</td><td align="left" colspan="1" rowspan="1">5 (4%)</td><td align="left" colspan="1" rowspan="1">7 (5%)</td></tr></tbody></table><table-wrap-foot><p>1Median (Q1, Q3); n (%)</p></table-wrap-foot></table-wrap>
</p><p id="Par13">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Univariable and multivariable Cox analyses in the overall cohort of 295 female urethral cancer patients with locally advanced stage</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="3" rowspan="1">Univariable Cox Analysis</th><th align="left" colspan="3" rowspan="1">Multivariable Cox Analysis *</th></tr><tr><th align="left" colspan="1" rowspan="1">
<bold>HR</bold>
<sup><bold>1</bold></sup>
</th><th align="left" colspan="1" rowspan="1">
<bold>95% CI</bold>
<sup><bold>1</bold></sup>
</th><th align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">p</italic></bold>
<bold>-value</bold>
</th><th align="left" colspan="1" rowspan="1">
<bold>HR</bold>
<sup><bold>1</bold></sup>
</th><th align="left" colspan="1" rowspan="1">
<bold>95% CI</bold>
<sup><bold>1</bold></sup>
</th><th align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">p</italic></bold>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CHT exposure</td><td align="left" colspan="1" rowspan="1">0.631</td><td align="left" colspan="1" rowspan="1">0.5, 0.9</td><td align="left" colspan="1" rowspan="1">
<bold>0.009</bold>
</td><td align="left" colspan="1" rowspan="1">0.670</td><td align="left" colspan="1" rowspan="1">0.5, 1.0</td><td align="left" colspan="1" rowspan="1">
<bold>0.027</bold>
</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>HR = Hazard Ratio, CI&#8201;=&#8201;Confidence Interval, CT&#8201;=&#8201;Chemotherapy</p></table-wrap-foot></table-wrap>
</p><p id="Par14">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Univariable and multivariable Cox analyses according to histological subtype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">SCC</th></tr><tr><th align="left" colspan="3" rowspan="1">Univariable Cox Analysis</th><th align="left" colspan="2" rowspan="1">Multivariable Cox Analysis *</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI<sup>1</sup>)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">HR<sup>1</sup></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CHT-exposure</td><td align="left" colspan="1" rowspan="1"><bold>0.63 (</bold>0.4, 0.9)</td><td align="left" colspan="1" rowspan="1">
<bold>0.009</bold>
</td><td align="left" colspan="1" rowspan="1"><bold>0.64 (0.4</bold>,<bold> 0.9)</bold></td><td align="left" colspan="1" rowspan="1">
<bold>0.01</bold>
</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">
<bold>UC</bold>
</th></tr><tr><th align="left" colspan="3" rowspan="1">
<bold>Univariable Cox Analysis</bold>
</th><th align="left" colspan="2" rowspan="1">
<bold>Multivariable Cox Analysis *</bold>
</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">
<bold>HR</bold>
<sup><bold>1</bold></sup>
<bold>(95% CI</bold>
<sup><bold>1</bold></sup>
<bold>)</bold>
</th><th align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">p</italic></bold>
<bold>-value</bold>
</th><th align="left" colspan="1" rowspan="1">
<bold>HR</bold>
<sup><bold>1</bold></sup>
</th><th align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">p</italic></bold>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CHT-exposure</td><td align="left" colspan="1" rowspan="1">0.62 (0.3, 1.3)</td><td align="left" colspan="1" rowspan="1">0.2</td><td align="left" colspan="1" rowspan="1">0.63 (0.3, 1.3)</td><td align="left" colspan="1" rowspan="1">0.2</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="5" rowspan="1">
<bold>ADK</bold>
</th></tr><tr><th align="left" colspan="3" rowspan="1">
<bold>Univariable Cox Analysis</bold>
</th><th align="left" colspan="2" rowspan="1">
<bold>Multivariable Cox Analysis *</bold>
</th></tr><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">
<bold>HR</bold>
<sup><bold>1</bold></sup>
<bold>(95% CI</bold>
<sup><bold>1</bold></sup>
<bold>)</bold>
</th><th align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">p</italic></bold>
<bold>-value</bold>
</th><th align="left" colspan="1" rowspan="1">
<bold>HR</bold>
<sup><bold>1</bold></sup>
</th><th align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">p</italic></bold>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">CHT-exposure</td><td align="left" colspan="1" rowspan="1"><bold>0.7 (</bold>0.5, 1.1)</td><td align="left" colspan="1" rowspan="1">
<bold>0.1</bold>
</td><td align="left" colspan="1" rowspan="1"><bold>0.7 (0.4</bold>,<bold> 1.0)</bold></td><td align="left" colspan="1" rowspan="1">
<bold>0.7</bold>
</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>HR = Hazard Ratio, CI&#8201;=&#8201;Confidence Interval, *adjusted for age</p><p>Abbreviations: SCC&#8201;=&#8201;squamous cell carcinoma, CHT&#8201;=&#8201;Chemotherapy, UC&#8201;=&#8201;urothelial carcinoma, CHT&#8201;=&#8201;Chemotherapy, ADK&#8201;=&#8201;Adenocarcioma, CHT&#8201;=&#8201;Chemotherapy</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec5"><title>Results</title><sec id="Sec6"><title>Descriptive characteristics</title><p id="Par15">In 295 locally advanced fPUC, median age was 65 years in CHT received vs. 66 years in CHT-na&#239;ve patients. Follow-up durations were longer in patients exposed to CHT vs. CHT-na&#239;ve patients (34 vs. 26 months). Regarding histological subtypes, 86 (29%) had UC, 70 (24%) SCC, 139 (47%) ADK. According to T-stage, patients exposed to CHT harbored more frequently T3/T4 stages than their CHT-na&#239;ve counterparts (77% vs. 69%). Similarly, patients exposed to CHT harbored more N1/N2 stages than their CHT-na&#239;ve counterparts (53 vs. 21%).</p></sec><sec id="Sec7"><title>Rates of chemotherapy over the study span (2000&#8211;2021)</title><p id="Par16">Of 295 locally advanced fPUC, 143 (48%) were exposed to CHT (Fig <xref rid="Fig3" ref-type="fig">3</xref>). According to study years, the absolute numbers ranged from 14/35 (40%) patients who underwent CHT in 2000&#8211;2001 to 18/29 (62%) patients in 2020&#8211;2021 The difference over time (&#916;22%) corresponded to an estimated annual percentage change of 2.9% (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01).</p></sec><sec id="Sec8"><title>Effect of chemotherapy on cancer specific mortality free survival in the overall cohort</title><p id="Par17">Five-year CSM rates in the overall cohort were 58 vs. 43% (&#916;15%) in CHT exposed vs. CHT na&#239;ve patients, respectively (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). These CSM rates yielded a univariable HR&#8201;=&#8201;0.63 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.009). After adjustment for age and histology, a multivariable HR&#8201;=&#8201;0.67 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.027) was recorded.</p><p id="Par18">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Rates of chemotherapy in locally advanced female urethral cancer patients and estimated annual percentage changes between 2000 and 2021 (years coupled)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1143" position="float" orientation="portrait" xlink:href="345_2025_5545_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec9"><title>Effect of chemotherapy on cancer specific mortality free survival in histological subgroups</title><p id="Par19">In SCC cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;70), 35 patients underwent CHT (50%). Five-year CSM rates were 57% vs. 42% (&#916;15%) in CHT exposed vs. CHT naive patients, respectively (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). These CSM rates resulted in a univariable HR&#8201;=&#8201;0.63 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.009). Adjusted for age, a multivariable HR&#8201;=&#8201;0.64 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01) was recorded.</p><p id="Par20">In UC cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;86), 50 patients underwent CHT (58%). Five-year CSM rates were 64 vs. 52% (&#916;12%) in CHT exposed vs. CHT naive patients, respectively (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). These CSM rates resulted in a univariable HR&#8201;=&#8201;0.62 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.2). Adjusted for age, a multivariable HR&#8201;=&#8201;0.63 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.2) was recorded.</p><p id="Par21">In ADK cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;139), 54 patients underwent CHT (40%). Five-years CSM rates were 54 vs. 42% in CHT exposed patients vs. CHT naive patients (&#916;12%), respectively (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C). These CSM rates resulted in a univariable HR&#8201;=&#8201;0.7 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.1). Adjusted for age, a multivariable HR&#8201;=&#8201;0.7 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.7) was recorded.</p></sec><sec id="Sec10"><title>Sample size and sample power calculations in UC and SCC subgroups</title><p id="Par22">Within UC subgroup, 50 vs. 36 patients were CHT exposed vs. CHT na&#239;ve. Assuming 36 patients in both arms with &#120572;=0.05, a power of 48% was recorded. In a more favourable scenario where 50 patients would be available in each arm with &#120572;=0.05, a power of 62% was recorded. To detect the observed difference of five-years CSM rates (&#916;12%) with ideally 80% power and &#120572;=0.05, at least 213 observations would have been required per arm.</p><p id="Par23">Within ADK subgroup, 56 vs. 83 patients were CHT exposed vs. CHT na&#239;ve. Assuming 50 patients in both arms with &#120572;=0.05, a power of 46% was recorded. In a more favourable scenario where 83 patients would be available in each arm with &#120572;=0.05, a power of 62% was recorded. To detect the observed difference of five-years CSM rates (&#916;12%) with ideally 80% power and &#120572;=0.05, at least 276 observations would have been required per arm.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par24">Within PUC, locally advanced staged patients may represent the subgroup where cancer control outcomes can be improved according to treatment intensification. However, treatment types and CSM rates in locally advanced fPUC are relatively unknown. We addressed this knowledge gap and made several noteworthy observations.</p><p id="Par25">First, PUC is very rare, especially in females [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In the current study, we only identified 295 locally advanced fPUC over a 22 year period (2000&#8211;2021). These numbers validate PUC-rarity, especially in females with locally advanced stage [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Of three existing studies that exclusively focused on fPUC, the sample sizes ranged from 32 to 91 patients [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR10">10</xref>]. However, none of these studies addressed locally advanced fPUC or the association between CHT and CSM. These knowledge gaps validate the pertinence of the current study that relied on the largest contemporary locally advanced fPUC cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;295) [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. </p><p id="Par26">Second, median age was 65 in the current study cohort. This is consistent with previous PUC studies that relied on mixed-sex PUC cohorts, where median age ranged from 60 to 66 years [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. When comparing female subgroups in mixed-sex PUC cohorts with the current study cohort, the proportions of histological subtypes are also similar [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Previous studies reported ADK as the most common subtype in female subgroups of mixed-sex PUC cohort, followed by UC and SCC [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. In the current study, most fPUC harbored ADK (47%), followed by UC (29%) and SCC (24%). These observations validate the current study population relative to previous studies that predominantly relied on male patient populations.</p><p id="Par27">Third, we addressed rates of CHT between 2000 and 2021. Out of 295 locally advanced fPUC, 141 patients underwent CHT (48%). The rate of CHT was higher than the ones reported in previous studies. For example, Dayyani et al. (2005&#8211;2009) reported on 40 of 140 PUC patients (29%) who underwent CHT. Gakis et al. (1993&#8211;2012) reported on 61 of 154 PUC patients (40%) in whom CHT was used [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. However, previous studies did not allow to separate males from females and ascertain the rates of CHT in female PUC patients alone. Moreover, the annual rates of CHT in locally advanced fPUC in the current study increased from 40% in the initial study years (2000&#8211;2001) to 62% in the final study years (2020&#8211;2021). This observation is both novel and encouraging and cannot be directly compared to previous studies.</p><p id="Par28">Fourth, we examined the association between CHT exposure and CSM in the overall fPUC cohort. Five-year CSM rates were 58 vs. 43% (&#916;15%) in CHT exposed vs. CHT naive patients, respectively (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). This resulted in a multivariable HR of 0.67 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.027) where CHT reached independent predictor status for lower CSM. This observation is also novel and encouraging. It validates the benefit of CHT in locally advanced fPUC patients in accordance with guideline recommendations. To the best of our knowledge, the current study represents a first objective validation that is based on strict statistical testing with proven independent predictor status. The observations cannot be directly compared to previous studies, since no previous studies examined locally advanced fPUC.</p><p id="Par29">Fifth, we examined the association between CHT exposure and CSM in specific histological subgroups. In SCC patients, five-year CSM rates were 57 vs. 42% (&#916;15%) in CHT-exposed vs. CHT naive patients, respectively. This resulted in a multivariable HR of 0.64 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01). In UC, five-year CSM rates were 64 vs. 52% (&#916;12%) in CHT exposed vs. CHT naive patients, respectively. This resulted in a multivariable HR of 0.63 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.2). In ADK cohort, five-years CSM rates were 54 vs. 42% (&#916;12%) in CHT-exposed vs. CHT naive patients, respectively. This resulted in a multivariable HR of 0.7 (<italic toggle="yes">p</italic>&#8201;=&#8201;0.7). Independent predictor status could only be recorded in SCC subgroup. Due to limited sample sizes, independent predictor status for lower CSM could not be recorded in UC and ADK subgroups. Lack of independent predictor status may predominantly be explained by small numbers of observations in those two subgroups, since the effect sizes were virtually the same across all three histological subtypes. Based on the sample sizes at hand, power calculations demonstrated severely limited power in UC (48&#8211;62%) and in ADK (46&#8211;62%) subgroups relative to ideal power of 80%. In consequence, availability of larger sample sizes might be expected to result in statistically significant differences and possibly independent predictor status of CHT for lower CSM in UC and ADK subgroupd. Unfortunately, it is unlikely that larger samples sizes may be identified in both subgroups.</p><p id="Par30">Taken together, fPUC is rare. Locally advanced fPUC is even more rare. CHT rates in fPUC have increased over time in accordance with guideline recommendations. The effect of CHT independently predicts lower CSM. This observation validates guideline recommendation for use of CHT in fPUC patients based on strict statistical testing with proven independent predictor status. Its effect is equally pronounced in all three histological subgroups. However, due to sample size limitations, the independent predictor status for lower CSM could only be validated in the SCC subgroup. These observations strongly suggest that CHT exposure may improve survival in a statistically significant, but more importantly, in a clinically meaningful fashion in locally advanced fPUC.</p><p id="Par31">Our study has several limitations due to the observational design and retrospective nature of the SEER database. Unfortunately, due to the rarity of fPUC, larger sample sizes than the ones recorded in the current study may not be expected. This sample size-/and power limitation will invariably undermine future studies that may be undertaken based on multi-institutional or other population databases. The National Cancer Database, that offers a larger pool of patients, may not provide meaningful answers when CHT is examined in the setting of locally advanced fPUC due to absence of CSM specific data. Finally, we could not address other patient&#8217;s variables that would have been used in ideal circumstances, such detailed as organ function, comorbidities or specific CHT eligibility criteria [<xref ref-type="bibr" rid="CR18">18</xref>], since these were not reported in the SEER database.</p></sec><sec id="Sec12"><title>Conclusion</title><p id="Par32">In fPUC patients, CHT use independently predicts substantially lower CSM. This effect also applies to SCC patients. The same relationship between CHT status and CSM is also operational in UC and ADK subgroups, but limited power undermined confirmation of its&#8217; statistical significance.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors reviewed the manuscript. Q.L. wrote the main manuscript text and prepared figures. Z.T. contributed to formal analyses. P.K., contributed to methodology, revision and scientific context, conzeptualization, supervision. F.C., F.S contributed to methodology, revision and scientific context. N.R., FD., MN., CC., A.M., M.L., F.F. contributed to analyses and reviews. C.C., C.S., L.K., contributed to conzeptualization. S.P., J.G., S.M., O.C., A.B., M.G., C.P., A.V. contributed to reviews.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by Projekt DEAL.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">EAU-Guidelines-on-Primary-Urethral-Carcinoma-2024.pdf. Accessed September 27 (2024) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Primary-Urethral-Carcinoma-2024.pdf">https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Primary-Urethral-Carcinoma-2024.pdf</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatta</surname><given-names>G</given-names></name><name name-style="western"><surname>van der Zwan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Casali</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Rare cancers are not so rare: the rare cancer burden in Europe</article-title><source>Eur J Cancer</source><year>2011</year><volume>47</volume><issue>17</issue><fpage>2493</fpage><lpage>2511</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.08.008</pub-id><pub-id pub-id-type="pmid">22033323</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gatta G, van der Zwan JM, Casali PG et al (2011) Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 47(17):2493&#8211;2511. 10.1016/j.ejca.2011.08.008<pub-id pub-id-type="pmid">22033323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2011.08.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenzel</surname><given-names>M</given-names></name><name name-style="western"><surname>Nocera</surname><given-names>L</given-names></name><name name-style="western"><surname>Coll&#224; Ruvolo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Incidence rates and contemporary trends in primary urethral cancer</article-title><source>Cancer Causes Control</source><year>2021</year><volume>32</volume><issue>6</issue><fpage>627</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1007/s10552-021-01416-2</pub-id><pub-id pub-id-type="pmid">33751293</pub-id><pub-id pub-id-type="pmcid">PMC8089076</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Wenzel M, Nocera L, Coll&#224; Ruvolo C et al (2021) Incidence rates and contemporary trends in primary urethral cancer. Cancer Causes Control 32(6):627&#8211;634. 10.1007/s10552-021-01416-2<pub-id pub-id-type="pmid">33751293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10552-021-01416-2</pub-id><pub-id pub-id-type="pmcid">PMC8089076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>W</given-names></name><name name-style="western"><surname>RoyChoudhury</surname><given-names>A</given-names></name><name name-style="western"><surname>Wenske</surname><given-names>S</given-names></name><name name-style="western"><surname>Decastro</surname><given-names>GJ</given-names></name><name name-style="western"><surname>McKiernan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>CB</given-names></name></person-group><article-title>Outcomes and prognostic factors of primary urethral Cancer</article-title><source>Urology</source><year>2017</year><volume>100</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2016.09.042</pub-id><pub-id pub-id-type="pmid">27720774</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sui W, RoyChoudhury A, Wenske S, Decastro GJ, McKiernan JM, Anderson CB (2017) Outcomes and prognostic factors of primary urethral Cancer. Urology 100:180&#8211;186. 10.1016/j.urology.2016.09.042<pub-id pub-id-type="pmid">27720774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urology.2016.09.042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenzel</surname><given-names>M</given-names></name><name name-style="western"><surname>Nocera</surname><given-names>L</given-names></name><name name-style="western"><surname>Coll&#224; Ruvolo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sex-Related differences include stage, histology, and survival in urethral Cancer patients</article-title><source>Clin Genitourin Cancer</source><year>2021</year><volume>19</volume><issue>2</issue><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.clgc.2020.12.001</pub-id><pub-id pub-id-type="pmid">33526327</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wenzel M, Nocera L, Coll&#224; Ruvolo C et al (2021) Sex-Related differences include stage, histology, and survival in urethral Cancer patients. Clin Genitourin Cancer 19(2):135&#8211;143. 10.1016/j.clgc.2020.12.001<pub-id pub-id-type="pmid">33526327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clgc.2020.12.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>TM</given-names></name><name name-style="western"><surname>Efstathiou</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma</article-title><source>World J Urol</source><year>2016</year><volume>34</volume><issue>1</issue><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1007/s00345-015-1583-7</pub-id><pub-id pub-id-type="pmid">25981402</pub-id><pub-id pub-id-type="pmcid">PMC10176500</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Gakis G, Morgan TM, Efstathiou JA et al (2016) Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol 34(1):97&#8211;103. 10.1007/s00345-015-1583-7<pub-id pub-id-type="pmid">25981402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-015-1583-7</pub-id><pub-id pub-id-type="pmcid">PMC10176500</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">SEER Incidence Data - SEER Data &amp;, Software SEER (2024) Accessed June 17. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://seer.cancer.gov/data/index.html">https://seer.cancer.gov/data/index.html</ext-link></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derksen</surname><given-names>JW</given-names></name><name name-style="western"><surname>Visser</surname><given-names>O</given-names></name><name name-style="western"><surname>de la Rivi&#232;re</surname><given-names>GB</given-names></name><name name-style="western"><surname>Meuleman</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Heldeweg</surname><given-names>EA</given-names></name><name name-style="western"><surname>Lagerveld</surname><given-names>BW</given-names></name></person-group><article-title>Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival</article-title><source>World J Urol</source><year>2013</year><volume>31</volume><issue>1</issue><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1007/s00345-012-0882-5</pub-id><pub-id pub-id-type="pmid">22614443</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Derksen JW, Visser O, de la Rivi&#232;re GB, Meuleman EJ, Heldeweg EA, Lagerveld BW (2013) Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. World J Urol 31(1):147&#8211;153. 10.1007/s00345-012-0882-5<pub-id pub-id-type="pmid">22614443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00345-012-0882-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Hong</surname><given-names>B</given-names></name></person-group><article-title>Clinical features and oncological outcomes of primary female urethral cancer</article-title><source>J Surg Oncol</source><year>2022</year><volume>125</volume><issue>5</issue><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1002/jso.26790</pub-id><pub-id pub-id-type="pmid">35050502</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lee W, Yu J, Lee JL, Kim YS, Hong B (2022) Clinical features and oncological outcomes of primary female urethral cancer. J Surg Oncol 125(5):907&#8211;915. 10.1002/jso.26790<pub-id pub-id-type="pmid">35050502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jso.26790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peyton</surname><given-names>CC</given-names></name><name name-style="western"><surname>Azizi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chipollini</surname><given-names>J</given-names></name><etal/></person-group><article-title>Survival outcomes associated with female primary urethral carcinoma: review of a single institutional experience</article-title><source>Clin Genitourin Cancer</source><year>2018</year><volume>16</volume><issue>5</issue><fpage>e1003</fpage><lpage>e1013</lpage><pub-id pub-id-type="doi">10.1016/j.clgc.2018.05.012</pub-id><pub-id pub-id-type="pmid">29859736</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Peyton CC, Azizi M, Chipollini J et al (2018) Survival outcomes associated with female primary urethral carcinoma: review of a single institutional experience. Clin Genitourin Cancer 16(5):e1003&#8211;e1013. 10.1016/j.clgc.2018.05.012<pub-id pub-id-type="pmid">29859736</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clgc.2018.05.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratama</surname><given-names>ME</given-names></name><name name-style="western"><surname>Ismy</surname><given-names>J</given-names></name><name name-style="western"><surname>Kamarlis</surname><given-names>R</given-names></name><name name-style="western"><surname>Mauny</surname><given-names>MP</given-names></name></person-group><article-title>Female primary urethral carcinoma: A rare case report</article-title><source>Int J Surg Case Rep</source><year>2021</year><volume>85</volume><fpage>106100</fpage><pub-id pub-id-type="doi">10.1016/j.ijscr.2021.106100</pub-id><pub-id pub-id-type="pmid">34311342</pub-id><pub-id pub-id-type="pmcid">PMC8326724</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Pratama ME, Ismy J, Kamarlis R, Mauny MP (2021) Female primary urethral carcinoma: A rare case report. Int J Surg Case Rep 85:106100. 10.1016/j.ijscr.2021.106100<pub-id pub-id-type="pmid">34311342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijscr.2021.106100</pub-id><pub-id pub-id-type="pmcid">PMC8326724</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Sharma A, Kumar PBB, Muthusamy RK, Mehta SS (2024) Advanced female urethral adenocarcinoma: A case report. Indian J Pathol Microbiol Published Online September 2. 10.4103/ijpm.ijpm_421_22<pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijpm.ijpm_421_22</pub-id><pub-id pub-id-type="pmid">39221890</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Management of primary female urethral adenocarcinoma: two rare case reports and literature review</article-title><source>Med Kaunas Lith</source><year>2023</year><volume>59</volume><issue>1</issue><fpage>109</fpage><pub-id pub-id-type="doi">10.3390/medicina59010109</pub-id><pub-id pub-id-type="pmcid">PMC9865078</pub-id><pub-id pub-id-type="pmid">36676733</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tian J, Zhu T, Xu Z et al (2023) Management of primary female urethral adenocarcinoma: two rare case reports and literature review. Med Kaunas Lith 59(1):109. 10.3390/medicina59010109<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/medicina59010109</pub-id><pub-id pub-id-type="pmcid">PMC9865078</pub-id><pub-id pub-id-type="pmid">36676733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayyani</surname><given-names>F</given-names></name><name name-style="western"><surname>Pettaway</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kamat</surname><given-names>AM</given-names></name><name name-style="western"><surname>Munsell</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sircar</surname><given-names>K</given-names></name><name name-style="western"><surname>Pagliaro</surname><given-names>LC</given-names></name></person-group><article-title>Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists</article-title><source>Urol Oncol</source><year>2012</year><volume>31</volume><issue>7</issue><fpage>1171</fpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2012.01.011</pub-id><pub-id pub-id-type="pmid">22534087</pub-id><pub-id pub-id-type="pmcid">PMC4131852</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC (2012) Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol 31(7):1171. 10.1016/j.urolonc.2012.01.011<pub-id pub-id-type="pmid">22534087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2012.01.011</pub-id><pub-id pub-id-type="pmcid">PMC4131852</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mano</surname><given-names>R</given-names></name><name name-style="western"><surname>Vertosick</surname><given-names>EA</given-names></name><name name-style="western"><surname>Sarcona</surname><given-names>J</given-names></name><etal/></person-group><article-title>Primary urethral Cancer&#8211; Treatment patterns and associated outcomes</article-title><source>BJU Int</source><year>2020</year><volume>126</volume><issue>3</issue><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1111/bju.15095</pub-id><pub-id pub-id-type="pmid">32336001</pub-id><pub-id pub-id-type="pmcid">PMC7483343</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Mano R, Vertosick EA, Sarcona J et al (2020) Primary urethral Cancer&#8211; Treatment patterns and associated outcomes. BJU Int 126(3):359&#8211;366. 10.1111/bju.15095<pub-id pub-id-type="pmid">32336001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bju.15095</pub-id><pub-id pub-id-type="pmcid">PMC7483343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aleksic</surname><given-names>I</given-names></name><name name-style="western"><surname>Rais-Bahrami</surname><given-names>S</given-names></name><name name-style="western"><surname>Daugherty</surname><given-names>M</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>PK</given-names></name><name name-style="western"><surname>Vourganti</surname><given-names>S</given-names></name><name name-style="western"><surname>Bratslavsky</surname><given-names>G</given-names></name></person-group><article-title>Primary urethral carcinoma: A surveillance, epidemiology, and end results data analysis identifying predictors of cancer-specific survival</article-title><source>Urol Ann</source><year>2018</year><volume>10</volume><issue>2</issue><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.4103/UA.UA_136_17</pub-id><pub-id pub-id-type="pmid">29719329</pub-id><pub-id pub-id-type="pmcid">PMC5907326</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Aleksic I, Rais-Bahrami S, Daugherty M, Agarwal PK, Vourganti S, Bratslavsky G (2018) Primary urethral carcinoma: A surveillance, epidemiology, and end results data analysis identifying predictors of cancer-specific survival. Urol Ann 10(2):170&#8211;174. 10.4103/UA.UA_136_17<pub-id pub-id-type="pmid">29719329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/UA.UA_136_17</pub-id><pub-id pub-id-type="pmcid">PMC5907326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>TM</given-names></name><name name-style="western"><surname>Daneshmand</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma</article-title><source>Ann Oncol Off J Eur Soc Med Oncol</source><year>2015</year><volume>26</volume><issue>8</issue><fpage>1754</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv230</pub-id><pub-id pub-id-type="pmid">25969370</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gakis G, Morgan TM, Daneshmand S et al (2015) Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol Off J Eur Soc Med Oncol 26(8):1754&#8211;1759. 10.1093/annonc/mdv230<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdv230</pub-id><pub-id pub-id-type="pmid">25969370</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Defining (2024) platinum-ineligible patients with metastatic urothelial cancer (mUC).| Journal of Clinical Oncology. Accessed October 30. 10.1200/JCO.2022.40.16_suppl.4577</mixed-citation></ref></ref-list></back></article></pmc-articleset>